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Where genetic predisposition to cancer exists we are used to
thinking of it as being familial or inherited in an autosomal
dominant manner, with the predisposition to the tumour
showing a high penetrance. An important development in
identifying some cancer genes has been the identification of
rare families with a high risk of developing specific tumours.
Genes important, for example, in the development of colonic
cancer in Adenomatous polyposis coli (APC) and breast
cancer in breast cancer families have been described. The
genes that are inherited in a mutated form in these families
may be the same genes that undergo mutation in somatic
cells of individuals without a familial predisposition, but still
resulting in the same tumour type. The best known example
of such a gene common to both inherited and sporadic forms
of tumour is the retinoblastoma gene. In the case of breast
cancer and colonic cancer the familial forms of the disease
have revealed genes which may be important in the much
more common non-familial form of the diseases. In the
familial form of specific cancers there may be no additional
phenotype other than presentation of the tumour itself, as in
retinoblastoma or breast cancer. In other familial cancers a
syndrome may be associated with tumour predisposition as
in WAGR syndrome (Wilm's aneridia genitourinary
anomalies and mental retardation) and Wilm's tumour or in
some cases of APC/Gardner's syndrome. Here familial
predisposition to a tumour is part of the syndrome.
It might also be expected that familial (Mendelian
dominant) predisposition to particular leukaemias might
exist. If so, it might occur either without an additional
phenotype or alternatively as part of a syndrome. Is there
any evidence for such familial predisposition to leukaemia
with high penetrance? In the case of an association with a
syndrome, neurofibromatosis (NFl) has been suggested to be
associated with different types of leukaemia. The strongest
evidence for an association of NF with leukaemia is the
reversal of the normal 4:1 ratio of ALL:ANLL to 9:20 in
NF families (Bader & Miller, 1978). Families ofchildren with
soft tissue sarcomas are characterised by an aggregation of
tumours including breast cancer in women. In 24 of these Li
Fraumeni families, 151 relatives were shown to have cancer.
The majority were sarcomas and breast cancers but about
7% were leukaemias, mainly ALL (Li et al., 1988). In a
subsequent study Birch et al. (1990) found fewer leukaemias.
There is, therefore, some evidence of familial leukaemia as
part of a syndrome or aggregation of tumours, although
these cases are very rare, and there is low penetrance of the
tumour phenotype.
Are there cases of familial leukaemia in the absence of an
associated syndrome? When considering this possibility it is
well to remember that leukaemia is both rare and
heterogeneous. When added to the possibility of less than
complete penetrance or weak predisposition then the
likelihood of observing familial cases is going to be slight.
These ideas have been discussed more generally by Ponder
(1990). It is not surprising, therefore, that there is no good
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evidence for familial cases of leukaemia not associated with a
syndrome. Draper et al. (1977) observed 20,000 cases of
childhood malignancy in the UK between 1953 and 1974 and
identified 12 sibling pairs with leukaemia. If a child has
leukaemia then the relative risk of a sib also developing
leukaemia is 2.3. Leukaemia in such siblings may be due to
associations between malignant disease and the presence of
particular predisposing genes, but of course the sharing of
common environmental factors may also be important. Ap-
parent absence of familial occurrence does not, of course,
preclude a considerable genetic predisposition in some indi-
viduals compared with others.
In addition, to dominant inheritance of predisposition to
cancer there are other forms of genetic predisposition. Fan-
coni's anaemia, Bloom's syndrome and ataxia telangiectasia
are all Mendelian recessive disorders where each shows
association with a form of leukaemia. The evidence for
predisposition to lymphoid leukaemia/lymphoma is partic-
ularly strong for patients with ataxia telangiectasia.
Ataxia telangiectasia is a progressive neurological disorder
with a birth incidence of about 1 in 300,000 (Swift et al.,
1986; Woods et al., 1990). Although generally believed to be
recessive, there is some suggestion that it may not always be
inherited as a Mendelian recessive disorder (Woods et al.,
1990). The major neurological features include progressive
ataxia presenting in infancy, oculomotor dyspraxia and
dysarthria. Immunodeficiency is a feature of this disorder,
although it is not severe. A majority, if not all patients have
a deficiency of cell mediated immunity, although deficiencies
of humoral immunity are much more variable. The resulting
predisposition to infection is very variable across the range of
patients. Most A-T patients show spontaneously occurring
chromosome abnormalities in lymphocytes, the most com-
mon of which are translocations involving chromosomes 7
and 14. These occur at levels 40-50 times greater than in
non-A-T individuals. Some translocation cells can proliferate
to produce clones as large as 90% of the circulating T cells.
The presence of these high levels of chromosome abnormality
is a useful aid to the diagnosis of the disorder. In addition,
use is also made of the greatly increased radiosensitivity of
A-T cells which can be measured either chromosomally or by
a colony forming assay. About 15% of patients, however,
show a relatively small increase in radiosensitivity, inter-
mediate between normal and most A-T patients, suggesting
some heterogeneity at the cellular level (Taylor et al., 1987).
About 10% of all AT homozygotes develop a malignancy
in childhood or early childhood. A minority of tumours are
epithelial cell cancers but with an unusually high predisposi-
tion to stomach carcinoma and smaller excesses of liver,
uterus and ovarian tumours. The vast majority of tumours
are, however, lymphoid in origin and all the leukaemias
reported by Spector et al. (1982) were lymphoid with no
myeloid tumours. A 70-fold and 250-fold excess for
leukaemias and lymphomas respectively was reported by
Morrell et al. (1986). Another intriguing point described by
Spector et al. was that in 8/20 A-T patients reported with
ALL, five tumours had markers for T cell leukaemia. This
compares with about 15% of cases of ALL expected with T
cell markers in a non-A-T population. Three out of the eight
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patients had T-cell chronic leukaemia and this tumour is
present in less than 5% of cases of all CLL in the non-A-T
population.
In the course of our recent linkage and genetic studies in
A-T we have visited 60 A-T families in the UK. In the total
of families visited we are aware of eight cases (five male and
three female) of leukaemia/lymphoma (in addition to two
further cases reported some years ago) (Table I), giving a
total of ten cases. The age at diagnosis of the tumour ranged
from under 2y to 43y. Six out of eight patients had a T cell
tumour, one showed a B cell lymphoma and the origin of
one case of ALL was uncertain. There are several points of
interest. (1) The ratio of T cell tumours to B cell tumours
was 6:1, clearly different from the ratio in the non-A-T
population. (2) In the children with T cell tumours 3/4 were
male, as expected from previous observations on childhood
leukaemias. These results, showing a male preponderance,
are similar to those presented by Spector et al. (1982). (3)
Our limited number of observations suggest that A-T
patients with T cell tumours can clearly be grouped into
either an older or younger category. Older patients with a
mean age of about 33 years have T cell chronic lymphocytic
leukaemia. Both of our patients 1 and 2 showed a prolifera-
tion of a lymphocyte clone, to 70%-100% of the T cell
population (inv(14)(ql lq32) and t(X;14) (q28;ql1) respec-
tively). The tumour arose from the clone following the
appearance of additional chromosomal translocations. There
are several other examples in the literature showing the
association between T-CLL and translocation clone prolifera-
tion in A-T patients in early adulthood (Table II). In some
A-T patients with chronic leukaemia (mature post-thymic
lymphocytes) progress of the disease may be as rapid as in
the later stages of acute T-cell leukaemia. The category of
younger patients (2-12 years in our group) developed T-cell
acute leukaemia/lymphoma. There is much less information
on the types of chromosomal change in the leukaemogenesis
in this group, but inv(14) and t(14;14) translocations are seen
(Tables I and II).
The characteristics of T-cell tumours in A-T and non-A-T
patients can be compared in the following way. In the non-
A-T population the early appearance of chromosome trans-
locations involving TCR genes occurs in both T-CLL and
T-ALL (Rabbitts, 1991). Primary chromosomal changes
associated with T-ALL in the non-A-T population involve a
wide range of translocations including t(1;14), t(7;19), t(7;9),
t(11;14), t(10;14) and others where a TCR gene is broken
(Rabbitts, 1991). In addition, occasional examples of t(14;14)
and inv(14) have been reported in T-ALL. In contrast, T-cell
chronic leukaemias in non-A-T patients do not show the
same variety of translocations and are most frequently char-
acterised by inv(14) and t(14;14) involving the TCRa gene
and different breakpoints over a wide region 3' of IgH. In
general, it might seem that the particular gene involved in the
initial translocation with the TCR gene may influence wheth-
er a chronic or acute tumour subsequently develops.
In A-T patients a single gene defect can produce an in-
creased susceptibility to both chronic and acute forms of T
cell leukaemia as well as T cell lymphoma. This might sug-
gest that different fundamental mechanisms are not necessary
for development of acute and chronic leukaemia.
A feature common to lymphocytes from all A-T patients
compared with normals is the 70-fold increased frequency of
T cell receptor hybrid genes (Lipkowitz et al., 1990). This is
likely to be a manifestation of the same gene defect giving
rise to the increased levels of chromosome translocations in
A-T.
In A-T patients without leukaemia the majority of spon-
taneous translocations have both breakpoints apparently
involving T cell receptor genes, e.g. inv(7). There is no
evidence that such translocations have a malignant potential.
There are, in addition, very frequent translocations in A-T
patients involving only one TCR gene, e.g. inv(14), t(14;14)
which have a leukaemic potential. Although the variety of
translocations associated with T-ALL in non-A-T patients
presumably also occurs in A-T patients these may be a much
smaller part of the total of translocations, compared with
non-A-T patients. The proportions of the different transloca-
tion cells with leukaemic potential will be different between
A-T and non-A-T patients. There are very few reports of the
cytogenetics of T-ALL in A-T patients but the two cases that
are known, very interestingly, involve inv(14) and t(14;14)
respectively (Tables I and II), which are very rare transloca-
tions in T-ALL in the non-A-T population. There are more
reports of the cytogenetics of T cell chronic leukaemias in
A-T patients where inv(14) and t(14;14) are commonly found
(Tables I and II) as is the case in the non-A-T population. It
seems, therefore, that the A-T gene defect allows the forma-
tion of a much higher level of particular translocations than
occurs in the non-A-T patients. These include translocations
with a leukaemic potential which are, because of the constitu-
tional defect, more numerous in A-T patients and also give
rise to both T cell chronic and acute leukaemias.
The events subsequent to the appearance of the initial
translocation and important in determining the development
of either acute or chronic forms of leukaemia might occur at
random in immature or mature cells respectively. Alterna-
tively, it is possible that in some patients there is preferential
development of either a chronic or acute T cell tumour. One
family showed two affected siblings, both of whom had large
translocation T cell clones and both developed T-CLL
(Levitt, 1978). In a second family with two affected siblings,
both again showed large translocation T cell clones and one
developed T-CLL (patient 1, Table I). Although based on
small numbers perhaps there is a suggestion of concordance
within families for development of both large translocation
clones over a period of time and chronic leukaemia. In a
Table I Leukaemia/lymphoma in ataxia telangiectasia patients in the UK
Age Chromosome Year oftumour
Patient (yrs) Sex Clinical disease rearrangement diagnosis
1 43 F T-CLL Complex but 1990
inc. t(X;14)
2a 27 M T-CLL Complex but 1984
inc. inv(14)
3* 12 F B cell lymphoma NK 1989
4* 11 F T-ALL Complex but 1991
inc. inv(14)
and t(7;19)
5* 7 M T-ALL NK 1990
6 6 M T cell lymphoma NK 1986
7*b 4 M ALL (B or T uncertain) NK 1984
8 <2 M T cell lymphoma NK 1990
9c 3 F Hodgkin's lymphoma NK 1978
10" 7 M Lymphoma NK 1974
*Families included in linkage study, McConville et al. (1990a and b). aTaylor and
Butterworth (1986), Baeretal. (1987). bEyreetal. (1988).cPritchardetal. (1982).dCunliffeet
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Table II Published cases of T cell tumours in ataxia telangiectasia
Age Chromosome
(yrs) Sex Clinical disease rearrangement Reference
48 F T-CLL t(l4;14)(ql l;q32) Sparkes et al. (1980)
Saxon et al. (1979)
Johnson et al. (1986)
Russo et al. (1989)
32 F T-CLL t(l4;14)(ql l;q32) Levitt et al. (1978)
Davey et al. (1988)
26 F T-CLL t(l4;14)(qll;q32) Levitt et al. (1978)
(subacute)
31 F T-CLL t(l4;14)(qll;q32) McCaw et al. (1975)
27 M T-CLL complex with 14q- Becher & Duhrsen (1987)
18 F T-ALL t(7;14)(q35;q32) Vitolo et al. (1984)
(mixed thymic Russo et al. (1988)
and mature)
18 F T-ALL t(l4;14)(qll;q32) Wake et al. (1982)
(tumour not from
clone)
12 M T-ALL complex with Minegishi et al. (1991)
(mixed thymic t(14;14)(qll;q32)
and mature)
10 M T-ALL NK Toledano & Large (1980)
12 M T-ALL NK Toledano & Large (1980)
14 M T-ALL NK Toledano & Large (1980)
13 M T-ALL NK Spector et al. (1982)
12 M T-ALL NK Cameron et al. (1977)
9 M T-cell lymphoma NK Miranda-
Valdievieso et al. (1987)
third family with two affected siblings one developed a large
T cell clone and subsequently a T-CLL but the other sibling
died from complications of a bronchial infection (patient 2,
Table I). Concordance for development ofALL was reported
by Morell et al. (1986) in an A-T sib pair. Similar concor-
dance for lymphoid tumours and stomach cancer was
reported by Spector et al. (1982).
Although the A-T gene in the homozygous state clearly
predisposes patients to leukaemia/lymphoma the gene may be
more important numerically in the heterozygous state. About
1% of the population carry the A-T gene (Swift et al., 1986)
and carriers have been reported to have a risk of cancer of
any type which is two to six times higher than for the normal
population. In a retrospective study Swift et al. (1987)
showed that cancer rates in adult blood relatives of A-T
patients were increased over rates in spouse controls with
rate ratios of 1.6 in men and 2.0 in women. When the
probability of carrying the gene was taken into account the
relative risk in adult carriers was estimated to be 2.1 for men
and 3.1 for women. The heterozygote relative risk for breast
cancer in women was significantly higher at 6.8. A sub-
sequent prospective study has confirmed the high risk of all
cancer among heterozygotes and particularly breast cancer in
women (Swift et al., 1991). If about 1% of the population
are carriers of the A-T gene then it has been estimated that
at least 10% of all breast cancers may occur in carriers ofthe
A-T gene. The evidence also suggests that diagnostic or
occupational exposure to ionising radiation probably in-
creases the risk of breast cancer in women carrying the A-T
gene (Swift et al., 1991). In addition to five breast cancers
diagnosed prospectively in a group of A-T obligate carriers,
13 other tumours were also diagnosed prospectively in the
test period. Previous data had suggested that the A-T gene
might additionally predispose the heterozygotes to cancers of
the pancreas, stomach, bladder, ovary and CLL (Swift et al.,
1990). Results from the prospective study were compatible
with an elevated risk of cancer of the lung, pancreas, gall
bladder and stomach. In both homozygous and heterozygous
states, the A-T gene appears to predispose to stomach
cancer. Two other studies have reported an excess of breast
cancer (although with very small figures) in carriers of the
A-T gene (Pippard et al., 1988; Boressen et al., 1990). In
neither study, however, was an excess of malignancies
observed in the grandparents of A-T patients, where half
would be expected to be A-T heterozygotes. Separate
estimates for the parental and grandparental generations of
excess cancer risk in heterozygotes were not given by Swift et
al. (1987), possible because of the different age distribution of
his families. It may not be possible to test whether a clear
association exists of the A-T gene in the heterozygous state
with other tumour types because of the paucity of tumours.
It is not known why there is apparently no obvious increased
risk in the heterozygotes of leukaemia/lymphoma, which are
the tumours most frequent in homozygotes. The A-T gene in
the homozygous state, however, clearly exerts a pleiotropic
effect in producing a range of clinical features and therefore
it is perhaps not surprising that the same pleiotropic effect
might operate at the level of cancer susceptibility.
The locus for A-T has been localised to chromosome
1 lq22-23 in a region associated with neurological and
immune function loci (Gatti et al., 1988; McConville et al.,
1990b). This assignment may represent either a single gene
or, in view of reports of at least four complementation
groups at least three ofwhich map to 1lq22-23, there may be
a number of genes in this region. Our linkage data provides
strong evidence for an A-T locus between the markers N-
CAM/DRD2 and STMY/CJ72.75, (p2.22. A recent paper
suggests that the gene for A-T group D may not be within
this region but telomeric to it (Lambert et al., 1991). In a
previous paper we had also shown evidence of linkage to the
Thy 1 regions of 1 lq22-23, with evidence of absence of
linkage in the intervening region between this and the more
centromeric locus (McConville et al., 1990a). The position of
possible different A-T loci is currently being investigated by
several groups.
Using about 20 markers on chromosome region l1q22-23
recombination events can be defined in order to localise the
position of the A-T gene. Haplotype analysis can also iden-
tify gene carriers within families with a high degree of
certainty. This heterozygote detection, together with epi-
demiological studies of the families, may help to clarify the
cancer risk associated with carrier status. Once the muta-
tion(s) for A-T has been identified there will be considerable
interest in estimating the frequency of A-T mutations in
breast cancer populations in order to test Swift's predictions
of the importance of the gene in breast cancer. Efforts at
establishing linkage of markers at 11q22-23 with premeno-
pausal bilateral breast cancer have not so far been successful8 A.M.R. TAYLOR
(Gatti, 1991). This may be due to the use of genetically
heterogeneous populations which may include, for example,
tumours where there is linkage to a gene on chromosome
17q.
Ataxia telangiectasia will continue to be an extremely
valuable model for understanding the development of
different tumour types both in heterozygotes and in
homozygotes. Despite the fact that leukaemias and lym-
phomas are in a category of tumours for which there is no
substantial evidence for familial predisposition there is very
clear evidence that in A-T the inherited gene defect con-
siderably increases the risk of lymphocytic leukaemia and
lymphoma.
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